Panel: Pharma's Partnership Priorities: Betting Smart, Not Just Big

Session details:

Large pharma is choosing fewer partners, more carefully. This panel explores how they are redefining value and risk in BD.

·       Identify why emerging biotech must prove more than just clinical potential

·       Assess how pharma is filtering opportunities with greater scrutiny

·       Learn how negotiation dynamics are shifting toward shared downside protection